What are the Medical & Investment Implication of Psychedelics
- Jonathan Poyer
- 9 hours ago
- 1 min read
Kennedy Capital's Anna Bunn, PhD and Ryan Dunnegan, CPA discuss the medical and investment implications of the new psychedelics.
This video features a discussion between Kennedy Capital's Anna Bunn, PhD, and Ryan Dunnegan, CPA, regarding the medical and investment potential of psychedelic-based therapies for conditions like depression and PTSD.
The experts explore the debate over whether the hallucinogenic "trip" is essential for therapeutic efficacy. They also analyze the shifting regulatory landscape and the market implications for investors looking at this emerging sector.
The conversation provides a comprehensive overview of how medical innovation in this field is intersecting with modern investment strategies.
Comments